Full Press Release Details
terna Zentaris Inc. 1405 du Parc-Technologique Blvd.
Qu bec (Qu bec) Canada G1P 4P5 T 418 652-8525 F 418 652-0881
terna Zentaris to Raise US$12 Million in Registered Direct Offering
Quebec City, Canada, June 15, 2010 terna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the
Company ), a late-stage drug development company specialized in oncology and endocrinology,
announced today that it has received commitments from institutional investors to purchase US$12.1
million of securities in a registered direct offering. Under the terms of a Securities Purchase
Agreement, the Company will sell to such institutional investors an aggregate of approximately 8.8
million common shares of its capital at a price of US$1.3725 per share and issue
warrants to acquire an aggregate of approximately 4.4 million common shares at an exercise price of
US$1.3725 per share.
The warrants to purchase additional common shares of terna Zentaris will be exercisable
immediately upon issuance and will expire on the fifth-year anniversary thereof. All of the
securities were offered pursuant to an effective shelf registration statement filed in the United
States. Proceeds from the transaction will be used to fund the Company s AEZS-108, AEZS-112 and
AEZS-130 programs and for other general corporate and working capital purposes. The offering is
expected to be consummated no later than June 18, 2010, subject to customary closing conditions.
Rodman Renshaw, LLC, a subsidiary of Rodman Renshaw Capital Group, Inc., (NASDAQ: RODM), acted
as the exclusive placement agent for the transaction.
The proceeds from terna Zentaris registered direct offering that was completed on April 20, 2010
have been and are being used primarily in connection with perifosine, terna Zentaris lead
oncology compound that is being developed in collaboration with its North American partner, Keryx
Biopharmaceuticals, Inc. (NASDAQ: KERX), following various positive developments announced with
respect to perifosine during the first quarter of 2010.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any
securities nor shall there be any sale of such securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification under the securities
laws of any such jurisdiction. A shelf registration statement relating to the common shares and
warrants issued in the offering (and the common shares issuable upon exercise of the warrants) has
been filed with the Securities and Exchange Commission (the SEC ) and has been
declared effective. A prospectus supplement relating to the offering will be filed by the Company
with the SEC and the Canadian securities regulatory authorities. Copies of the prospectus
supplement and accompanying prospectus may be obtained directly from the Company or by contacting
terna Zentaris Inc., 1405 du Parc-Technologique Boulevard, Quebec City, Canada G1P 4P5.
About terna Zentaris Inc.
terna Zentaris Inc. is a late-stage drug development company specialized in oncology and
endocrine therapy News releases and additional information are available at www.aezsinc.com.
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions
of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and
unknown risks and uncertainties, which could cause the Company s actual results to differ
materially from those in the forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue R D projects, the successful and
timely completion of clinical studies, the ability of the Company to take advantage of business
opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and
general changes in economic conditions. Investors should consult the Company s quarterly and annual
filings with the Canadian and U.S. securities commissions for additional information on risks and
uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on
these forward-looking statements. The Company does not undertake to update these forward-looking
statements. We disclaim any obligation to update any such factors or to publicly announce the
result of any revisions to any of the forward-looking statements contained herein to reflect future
results, events or developments except if we are required by a governmental authority or applicable
Investor Relations Coordinator
(418) 652-8525 ext. 265
Director of Communications
(418) 652-8525 ext. 406